Search
Other COVID-19 Resources
Safety of COVID-19 vaccines – April updates
ECDC and EMA issue advice on fourth doses of mRNA COVID-19 vaccines
EMA recommends authorisation of COVID-19 medicine Evusheld
EMA recommends authorisation of booster doses of Comirnaty from 12 years of age
EMA recommends approval of Spikevax…
Committees and units
The EHA Board sets up committees and units to perform specific tasks and activities.
Read moreMeeting program
October 11, 2023 at 3 pm CET The interaction of von Willebrand factor (VWF) with platelet glycoprotein Ib: pathological implications and clinical manifestations
15:00-15:10 Introduction Giancarlo Castaman, Paolo Gresele …
EPICOVIDEHA survey
COVID-19 infections in patients with Hematological Malignancies - Results from EHA-IDWP registry
EPICOVIDEHA is an international open web-based registry for patients with haematological malignancies infected with SARS-CoV-2,
The survey has been approved by the Institutional Review Board and Ethics Committee of the…
SWG Educational Activities
EHA-SWG meeting at EHA2023Date and timeThursday, June 8, 2023, from 16. 00–18. 00. LocationFrankfurt, Germany. Chairs
A Taher
A Iolascon
EHA-SWG scientific meetingMeeting topic and title‘Red Cell and Iron Metabolism Defects: From Basic Science to Clinical Case Application.
Tools and Overview Tables
EHA2023 session on COVID-19 and influenzaThe SWG suggested the above session, which was held during the EHA 2023 Hybrid Congress. Full titleCOVID-19 and influenza in patients with hematological malignancies.
Read morePublications
Experience With IVDR Implementation in Three Diagnostic Laboratories: Messages to EU Health Institutions, Diagnostic Healthcare Payers, and Authorities
Lubbers BR, Dombrink I, Kalina T, Hofmans M, Bruun MS, Stanworth SJ, Béné MC, Döhner K, Brüggemann M, Macintyre E, van Dongen JJM.…
Publications
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.
Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)
CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- »